<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9917">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687539</url>
  </required_header>
  <id_info>
    <org_study_id>MASTIHA-WATER-551</org_study_id>
    <nct_id>NCT05687539</nct_id>
  </id_info>
  <brief_title>Mastiha or Mastiha Water in Functional Dyspepsia</brief_title>
  <official_title>The Effect of Mastiha Products on Functional Dyspepsia. A Randomised Crossover Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harokopio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harokopio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to establish whether Mastiha products ameliorate functional&#xD;
      dyspepsia symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional dyspepsia has an approximate prevalence of 20% and is one of the main causes of&#xD;
      upper abdominal discomfort. Its pathogenesis remain unclear and therapeutic options remain&#xD;
      limited with patients seeking alternative therapies in herbal remedies. Mastiha has been&#xD;
      proven to significantly improve symptoms in patients with functional dyspepsia compared to&#xD;
      placebo. In the present study, the investigators aim to determine whether Mastiha capsules or&#xD;
      Mastiha water have a better effect on the improvement of functional dyspepsia symptoms.&#xD;
      Therefore, the investigators designed a randomized, three-way cross-over clinical trial.&#xD;
      Fifty patients with functional dyspepsia, will be randomized over three treatment sequences&#xD;
      of 30 days each, separated by 14-day washout periods. The three treatments will be: Mastiha&#xD;
      capsules, Mastiha water or Mastiha free treatment. The primary outcome, which will be&#xD;
      assessed by intention to treat, will be the Leuven Postprandial Distress Scale, a validated&#xD;
      instrument for the assessment of symptoms in functional dyspepsia, supported by the European&#xD;
      Medicines Agency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">October 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Leuven Postprandial Distress Scale (LPDS)</measure>
    <time_frame>1 month</time_frame>
    <description>The change in Leuven Postprandial Distress Scale will be evaluated at follow-up. LPDS minimum score is 0 and maximum 32. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>1 month</time_frame>
    <description>Change in quality of life at follow-up as assessed via the EQ-5D-5L questionnaire. EQ-5D-5L has a scale from 0 to 100, with higher scores meaning better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sense of adequate relief</measure>
    <time_frame>1 month</time_frame>
    <description>The percentage of patients with adequate relief of symptoms will be evaluated at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of medicines</measure>
    <time_frame>1 month</time_frame>
    <description>The percentage of patients that decreased drug dose of medicines for functional dyspepsia will be evaluated at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety</measure>
    <time_frame>1 month</time_frame>
    <description>Change in anxiety at follow-up as assessed via the GAD-7 ANXIETY questionnaire. GAD-7 ANXIETY has a scale from 0 to 21, with higher scores meaning worse outcomes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Mastiha water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10ml of Mastiha water before every meal for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mastiha capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 2 Mastiha capsules (2x350mg) before every meal for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-Mastiha free</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will follow a Mastiha free one month period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mastiha water</intervention_name>
    <description>10ml of mastiha water before every meal for one month</description>
    <arm_group_label>Mastiha water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mastiha capsules</intervention_name>
    <description>2x350mg mastiha capsules before every meal for one month</description>
    <arm_group_label>Mastiha capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        functional dyspepsia diagnosis according to&#xD;
&#xD;
          -  Rome criteria&#xD;
&#xD;
          -  negative urea breath test for Helicobacter pylori&#xD;
&#xD;
          -  upper gastrointestinal tract endoscopy with biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  organic diseases, such as peptic ulcer, gastrointestinal neoplasms, gastroesophageal&#xD;
             reflux, irritable bowel syndrome&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  history of abdominal surgery or actinotherapy&#xD;
&#xD;
          -  mental illness&#xD;
&#xD;
          -  Severe impairment of heart, liver, or kidney function or respiratory function&#xD;
&#xD;
          -  Alcohol overuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andriana C. Kaliora, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Harokopio University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andriana Kaliora, Ass. Prof.</last_name>
    <phone>00302109549226</phone>
    <email>akaliora@hua.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Andriana Kaliora</name>
      <address>
        <city>Athens</city>
        <zip>17671</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andriana C Kaliora, Ass. Prof</last_name>
      <phone>+30 2109549226</phone>
      <email>akaliora@hua.gr</email>
    </contact>
    <investigator>
      <last_name>Andriana C Kaliora, Ass. Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 28, 2022</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harokopio University</investigator_affiliation>
    <investigator_full_name>Andriana C Kaliora</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

